WAVE Life Sciences (STU:1U5) FCF Margin % : -52.22% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. WAVE Life Sciences's Free Cash Flow for the three months ended in Dec. 2024 was €-41.8 Mil. WAVE Life Sciences's Revenue for the three months ended in Dec. 2024 was €80.0 Mil. Therefore, WAVE Life Sciences's FCF Margin % for the quarter that ended in Dec. 2024 was -52.22%.

As of today, WAVE Life Sciences's current FCF Yield % is -10.24%.

The historical rank and industry rank for WAVE Life Sciences's FCF Margin % or its related term are showing as below:

STU:1U5' s FCF Margin % Range Over the Past 10 Years
Min: -9463.16 Med: -893.28 Max: -18.13
Current: -136.74

During the past 12 years, the highest FCF Margin % of WAVE Life Sciences was -18.13%. The lowest was -9463.16%. And the median was -893.28%.

STU:1U5's FCF Margin % is ranked better than
50.2% of 1022 companies
in the Biotechnology industry
Industry Median: -143.22 vs STU:1U5: -136.74

WAVE Life Sciences FCF Margin % Historical Data

The historical data trend for WAVE Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences FCF Margin % Chart

WAVE Life Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-584.36

-218.62

-3,538.75

-18.13

-140.32

WAVE Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-115.62	-269.97	-139.75	610.50	-52.22

Competitive Comparison of WAVE Life Sciences's FCF Margin %

For the Biotechnology subindustry, WAVE Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WAVE Life Sciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's FCF Margin % falls into.

WAVE Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

WAVE Life Sciences's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-145.126	/	103.428
	=	-140.32 %

WAVE Life Sciences's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-41.766	/	79.979
	=	-52.22 %

WAVE Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

WVE:USA 1U5:Germany

Address

7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines